Recommendations for Dosing of LUPKYNIS, Along With MMF and Low-dose Steroids (≤2.5 mg/day)1a
Starting dose
23.7 mg BID
3 capsules
(7.9 mg each)
BID
12-hour
schedule
Taken as close
as possible to
scheduleb
Empty
stomach
1 hour before
or 2 hours
after meal
Swallow
whole
Should not open,
crush, or divide
capsules
No drug-level monitoring required.1
Assess eGFR Every 2 Weeks for the First Month, and Every 4 Weeks Thereafter, and Adjust Dose as Necessary1c
eGFR ≥60 mL/min/1.73 m2
No dose adjustment necessary;
continue 3 capsules BID
eGFR <60 mL/min/1.73 m2
≤20% reduction
from baseline
No dose adjustment necessary; continue 3 capsules BID
>20% and <30%
reduction from
baseline
Reduce dose to 2 capsules BID
Reassess eGFR within 2 weeks; if still >20% reduced from baseline: reduce dose to 1 capsule BID
Reassess eGFR within 2 weeks; if ≥80% of baseline, consider increasing dose by 1 capsule BID; do not exceed starting dose
≥30% reduction
from baseline
Discontinue
LUPKYNIS
Reassess eGFR within 2 weeks; if ≥80% of baseline, consider restarting at 1 capsule BID
cThe phase 3 study was designed to allow for dose modifications due to eGFR reductions.1
- Dose adjustments may be required for patients with eGFR reductions, renal impairment, hepatic impairment, or drug interactions with moderate CYP3A4 inhibitors1
- Monitor blood pressure every 2 weeks for the first month of treatment, and as clinically indicated thereafter1
- For blood pressure >165/105 mmHg, discontinue LUPKYNIS and initiate antihypertensive therapy
- Please see the Prescribing Information for specific dose adjustment recommendations
aLUPKYNIS is indicated in combination with MMF and steroids for the treatment of adult patients with active LN.1
bDose should be taken within 4 hours. Beyond 4 hours, wait until next scheduled dose; do not double the dose.1
BID=twice daily; eGFR=estimated glomerular filtration rate; FDA=Food and Drug Administration; MMF=mycophenolate mofetil.
Reference: 1. LUPKYNIS. Package insert. Aurinia Pharma U.S., Inc; 2024.
